Abbott (NYSE:ABT) offered additional details on its up-coming split, which will result in a new standalone pharmaceutical and biologics arm dubbed AbbVie.
Theragenics Corp.
Theragenics alters executive non-compete agreements to more “enforceable” format | Personnel Moves
FDA clears Ethicon’s 1st surgical set docs can assemble inside the body | Regulatory Roundup
Johnson & Johnson (NYSE:JNJ) Ethicon Endo-Surgery won FDA clearance for the 1st surgical instruments that can be assembled and disassembled inside the body during surgery.
NuVasive swings to Q4, 2011 red | Earnings Roundup
NuVasive (NSDQ:NUVA) swung to red for the 4th quarter and full-year 2011, largely on the back of an $18.2 million writedown of intangible assets.
The San Diego-based spinal implant maker posted a loss of $10.0 million, or 24 cents per share, on sales of $150.2 million for the 3 months ended Dec. 31, 2012. That’s a top-line gain of 16.2% compared with Q4 2010, when NuVasive posted profits of $61.9 million, or $1.39 EPS.
Is Medtronic’s spine business headed to the auction block? | Wall Street Beat
The message to Medtronic’s (NYSE:MDT) spine business from chairman and CEO Omar Ishrak was clear today: Shape up or ship out.
During a conference call with analysts to discuss the med-tech titan’s fiscal 3rd-quarter results, Ishrak said he was “not happy” that the division posted a 9% revenue decline and warned that the spine unit must raise its game or face the consequences.
Supreme Court considers medical patents | Legal News
The U.S. Supreme Court heard oral arguments this week in a case that could have wide-reaching implications for health care: Whether medical patents should be allowed.
At issue is the specter of doctors being sued for patent infringement based on treatment decisions derived from the scientific research underpinning the patent.
PerkinElmer Q1 profits inch downward despite 14 percent sales increase | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Theragenics turns down takeover proposal | Acquisitions roundup
Theragenics Corp. (NYSE:TGX) won’t go for a bargain price, company officials said last week.
Insulet’s Q4 losses widen but 2010 losses fall 16 percent | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Earnings roundup: Insulet revenue jumps 36 percent as losses narrow
Insulet revenue jumps 36 percent as losses narrow
Insulet Corp. (NSDQ:PODD) reported a loss of $12.1 million, or 30 cents per diluted share, on revenue of $25.5 million during the three months ended Sept. 30. That compares with a loss of $16.9 million, or 60 cents per diluted share, on revenue of $18.7 million during the same period last year.
Theragenics swings to Q4, 2009 black
Theragenics Corp. (NYSE:TGX) posted fourth-quarter sales of $18.7 million for the three months ended Dec. 31, 2009, up 3.2 percent compared with $18.1 million during the same period in 2008. Net income was $389,000, compared with net losses of $62.5 million during Q4 2008:
Press Release
Theragenics® Reports Record Revenue with
2009 Results
$78.3 Million is Highest Annual Revenue in 29-Year History